Diabetes mellitus is a metabolic diseases, mainly including type 1 and type 2 diabetes. The aim of this study was to examine the impact of diabetes on mesenchymal stem cells (MSCs) during fracture repair. The use of human-derived cells was approved by the Institutional Biomedical Research Ethics Committee of the Chinese Academy of Medical Science and Peking Union Medical College. The chimeric gene also contained a hygromycin resistance gene (pGK-hygro) to select transfected cells. The findings appear in the October 1 issue of Cell Stem Cell, accompanied by an editorial commentary. Scientists, led by Shoukhrat Mitalipov of Oregon Health & Science University, reported they had created healthy, early-stage human embryos – hollow balls of about 150 cells – by fusing ova with cells from a fetus, in one experiment, and an infant in another. Single-cell transcriptional analysis identified a subpopulation of cells which was diminished in both type 1 and type 2 models of diabetes.
All cells used in this study were from the third and fourth passages of MSC. Six of the patients, who had moderate type 1 diabetes, were able to lower their insulin dosage by 38% 12 weeks after the treatment. Therefore, direct effects on MSCs may be responsible for some of the orthopaedic effects associated with diabetes. However, this approach is limited by the availability of donor cells and the side effects of immunosuppression. Similarly, 21.5% of patients were improved as their dosage regimen for using oral drugs was reduced to 1-2 from 5.